Colorectal cancer remains a leading cause of cancer-related morbidity and mortality worldwide, making insights into its cellular mechanisms a top priority for oncological research. Central to the cellular fate decisions are the processes of autophagy—a catabolic mechanism that recycles cellular components to sustain cell survival under stress—and apoptosis, the programmed cell death that serves as a natural barrier against cancer progression. Glycoproteins, proteins with attached carbohydrate groups, emerge as pivotal regulators within this duality, influencing signaling pathways that dictate tumor behavior.

The review meticulously catalogs the diverse family of glycoproteins implicated in colorectal cancer, emphasizing their roles both as mediators and modulators of autophagy and apoptosis. These macromolecules, often situated on the cell surface or secreted into the tumor microenvironment, orchestrate complex interactions between cancerous cells and their surroundings, impacting tumor growth, metastasis, and therapy resistance.

One of the critical revelations from this analysis is the dualistic nature of certain glycoproteins, which can sway the balance towards either promoting cell survival or instigating cell death, depending on the contextual cues and intracellular signaling networks. For instance, some glycoproteins facilitate the induction of autophagy as a protective mechanism against chemotherapeutic agents, thereby enabling cancer cells to endure adverse conditions. Conversely, others activate apoptotic pathways, curbing tumor expansion.

The authors highlight the emerging therapeutic potential of targeting glycoproteins to manipulate autophagy and apoptosis. This could revolutionize colorectal cancer treatment by sensitizing tumor cells to existing therapies or by reprogramming resistant cells toward programmed death. The cross-talk orchestrated by glycoproteins suggests a fine regulatory system that could be exploited pharmacologically to tilt the intracellular environment unfavorably for cancer cell survival.

Autophagy, traditionally viewed as a survival mechanism under metabolic stress, is now recognized for its paradoxical role in cancer, where its modulation can either suppress or promote tumorigenesis. The review dissects how glycoproteins regulate this process through modulation of key autophagic markers and signaling axes such as mTOR, AMPK, and Beclin-1. By fine-tuning these pathways, glycoproteins influence the degradative machinery within colorectal cancer cells, potentially altering their susceptibility to apoptosis.

Apoptosis, the programmed cell death mechanism, is no less complexly regulated by glycoproteins. These molecules affect apoptotic signaling cascades including the intrinsic mitochondrial pathway and the extrinsic death receptor pathway. Changes in glycoprotein expression or function can result in either the evasion of apoptosis, a hallmark of cancer, or the promotion of cell death, which constrains tumor growth.

Moreover, the tumor microenvironment, shaped significantly by glycoproteins, emerges as a dynamic arena where autophagy and apoptosis intersect. Glycoproteins contribute to immune evasion, angiogenesis, and intercellular communication, all of which feed back into the cancer cell survival machinery. The review elucidates the multifaceted influences these molecules exert beyond the cancer cell itself, encompassing stromal and immune components.

The review also illuminates the challenges in deciphering the glycoprotein landscape due to the structural heterogeneity of glycosylation patterns. These variations profoundly impact glycoprotein function, localization, and interactions. Advances in glycoproteomics and analytical techniques are crucial in unraveling this complexity, offering pathways to identify novel biomarkers and therapeutic targets.

Therapeutic interventions aiming at glycoproteins encompass monoclonal antibodies, small molecule inhibitors, and glycomimetic agents designed to disrupt aberrant glycoprotein-mediated pathways. Clinical trials increasingly incorporate these approaches, underscoring the translational significance of understanding glycoprotein roles in autophagy and apoptosis.

Additionally, the interplay between glycoproteins and genetic and epigenetic alterations in colorectal cancer cells adds further layers of regulation. These interactions can potentiate oncogenic signaling or compromise apoptotic responses, highlighting the importance of integrated molecular studies to design effective combinational therapies.

The authors advocate for more in-depth studies to resolve outstanding questions regarding the temporal and spatial dynamics of glycoprotein function in cancer cells. Particularly, the contextual dependency of glycoprotein-mediated autophagy and apoptosis signaling demands comprehensive investigations utilizing advanced in vitro and in vivo models.

In summary, this exhaustive review sets the stage for a new era in colorectal cancer research, emphasizing glycoproteins as master regulators of cell fate decisions. The molecular insights gathered could pave the way for innovative diagnostic and therapeutic strategies that improve patient outcomes by precisely targeting these glycosylated proteins within the autophagy and apoptosis nexus.

The ongoing exploration of glycoprotein-mediated mechanisms promises to unravel the complexities of colorectal cancer pathobiology further, enabling the creation of more effective, targeted, and personalized treatments. As the scientific community continues to decode these glycomolecular codes, a future where colorectal cancer is more controllable and survivable appears increasingly attainable.

The implications of manipulating glycoprotein functions extend beyond colorectal cancer, potentially offering broader applications in oncology and regenerative medicine. Understanding the fundamental roles these molecules play at the intersection of autophagy and apoptosis could inform therapeutic approaches across a wide spectrum of diseases characterized by dysregulated cell death and survival.

This comprehensive scoping review marks a pivotal step towards harnessing glycoproteins as both biomarkers and functional targets, with the inspiring prospect of transforming the therapeutic landscape and offering renewed hope to colorectal cancer patients worldwide.

Subject of Research: The regulatory role of glycoproteins in autophagy and apoptosis pathways in colorectal cancer.

Article Title: The role of glycoproteins in autophagy and apoptosis in colorectal cancer: A scoping review.

Article References:
Ali Ibrahim Mze, A., Abdul Rahman, A., Ibahim, M.J. et al. The role of glycoproteins in autophagy and apoptosis in colorectal cancer: A scoping review. Med Oncol 43, 110 (2026). https://doi.org/10.1007/s12032-025-03197-z

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-025-03197-z

The tumor microenvironment operates as a tense metabolic arena where cancer cells relentlessly consume available amino acids, depriving immune cells of essential substrates necessary for their activation and survival. Glutamine, for instance, is avidly taken up by tumor cells through the overexpression of the transporter SLC1A5. This increased glutamine uptake fuels the tricarboxylic acid (TCA) cycle, supporting tumor bioenergetics and biosynthesis. Concurrently, glutamine metabolism enhances the expression of programmed death-ligand 1 (PD-L1), a crucial immune checkpoint molecule that binds PD-1 receptors on CD8⁺ T cells and inhibits T cell receptor (TCR) signaling. The consequence is a suppression of cytotoxic T lymphocyte activation and the induction of T cell exhaustion, undermining antitumor immunity at a fundamental level.

Simultaneously, the depletion of glutamine in the extracellular milieu compromises T cell metabolic fitness. T cells require glutamine to maintain TCA cycle function and to support their rapid proliferation and effector capabilities. Thus, the tumor’s monopolization of glutamine creates a metabolic void that weakens immune surveillance. This insight highlights how amino acid scarcity in the TIME does not merely reflect nutrient competition but constitutes a deliberate, tumor-driven sabotage of T cell efficacy. The dual role of glutamine in both tumor promotion and immune suppression underscores its critical position as a target for therapeutic intervention designed to restore immune competence.

Tryptophan metabolism illustrates another mechanism by which tumors subvert immune function. Cancer cells overconsume tryptophan and enzymatically convert it into kynurenine via indoleamine 2,3-dioxygenase (IDO). Kynurenine acts as a ligand for the aryl hydrocarbon receptor (AhR) in T cells, initiating a signaling cascade that downregulates co-stimulatory molecules such as CD80 and CD86 while upregulating PD-1 expression. This molecular reprogramming suppresses T cell activation and reinforces an immunosuppressive microenvironment conducive to tumor growth. The tryptophan-kynurenine-AhR axis exemplifies how tumor metabolism can directly modulate immune checkpoints and cellular phenotypes to promote tolerance rather than attack.

Beyond T cells, amino acid metabolism profoundly affects macrophage polarization and function within the TIME. Serine, metabolized through the serine–glycine–one-carbon (SGOC) pathway under the control of activating transcription factor 4 (ATF4), supports nucleotide synthesis and tumor proliferation. Tumor cells elevate serine uptake to enable this biosynthetic demand, again starving immune cells of resources. Intriguingly, serine deprivation has been shown to induce M1 macrophage polarization, a phenotype associated with pro-inflammatory and antitumor activity, mediated by upregulation of insulin-like growth factor 1 (IGF1) and activation of signal transducer and activator of transcription 1 (STAT1) signaling. This suggests that manipulating serine availability could be a viable strategy to reprogram macrophages towards an immunostimulatory state.

Arginine metabolism represents another axis exploited by tumor-associated myeloid cells to suppress immunity. Tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) express arginase 1 (ARG1), which catabolizes extracellular arginine, a critical amino acid for T cell activation and proliferation. The depletion of arginine in the TIME impairs T cell receptor signaling and proliferation, effectively blunting immune responses. Additionally, the production of nitric oxide (NO) by these cells further contributes to immunosuppression. Regulatory T cells (Tregs) secrete immunosuppressive cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), reinforcing the immunosuppressive milieu and sustaining tumor tolerance.

The interplay of amino acid sensing pathways underpins how immune cells detect and respond to metabolic stress within the TIME. Key sensors such as the mechanistic target of rapamycin (mTOR), AMP-activated protein kinase (AMPK), and AhR interpret fluctuations in amino acid availability, triggering intracellular signaling networks that control cell survival, proliferation, and immune evasion. Newly identified molecular sensors, including mitochondrial threonyl-tRNA synthetase 2 (TARS2) and histone deacetylase 6 (HDAC6), expand our understanding of amino acid signaling and suggest novel targets for therapeutic modulation. These sensors act as metabolic gatekeepers, linking nutrient status to epigenetic and transcriptional control of immune and tumor cell behavior.

Capitalizing on this growing knowledge, innovative therapeutic strategies are emerging to manipulate amino acid metabolism and reprogram the TIME. Glutaminase inhibitors, which block glutamine utilization in tumor cells, aim to restore glutamine levels and metabolic fitness in T cells. Similarly, arginase inhibitors prevent arginine depletion, enhancing T cell activation. Dietary interventions restricting methionine intake are under investigation for their capacity to influence DNA methylation and epigenetic programming in tumor and immune cells alike. Moreover, amino acid-loaded nanoparticles offer targeted delivery systems to modulate local nutrient composition, while microbial-based therapies leverage the gut and tumor-associated microbiota to influence amino acid availability and immune responses.

Some of the most groundbreaking advances involve the engineering of immune cells with enhanced nutrient-sensing abilities or metabolic resilience. CAR-T cells optimized for amino acid metabolism exhibit improved persistence and antitumor efficacy in nutrient-deprived microenvironments. Similarly, probiotics designed to alter amino acid metabolite profiles within the gut or tumor niche represent a frontier for modulating systemic and local immunity. These approaches reflect a paradigm shift towards metabolic immunotherapy that integrates cellular programming with microenvironmental regulation.

The insights provided by the comprehensive review from Tongji University Cancer Center position amino acid metabolism as a central language through which tumors and immune cells communicate. Interrupting this metabolic dialogue presents unprecedented opportunities to overcome immune resistance and improve cancer treatment outcomes. By combining metabolic inhibitors with established immune checkpoint blockade or adoptive cell therapies, a synergistic effect can be achieved that not only halts tumor growth but also revives exhausted immune cells.

As metabolic profiling technologies become increasingly sophisticated, the prospect of personalized cancer treatment driven by metabolic phenotyping looms. Tailoring therapies to the metabolic landscapes of individual tumors and their immune microenvironments holds promise for enhancing therapeutic specificity and minimizing off-target effects. Amino acid metabolism emerges not only as a biomarker for disease progression but also as a lever for therapeutic intervention that may redefine future standards in oncology.

In conclusion, the dynamic and reciprocal regulation of amino acid availability and sensing profoundly shapes the tumor immune microenvironment, influencing tumor progression, immune suppression, and therapeutic response. Continued research in this field is vital to unravel the molecular intricacies of metabolic competition and to translate these findings into innovative, effective cancer therapies. The expanding toolkit of metabolic and immunologic interventions heralds a new era in which harnessing amino acid pathways may unlock the full potential of antitumor immunity and improve patient survival worldwide.

Subject of Research:
Not applicable

Article Title:
Amino acids shape the metabolic and immunologic landscape in the tumor immune microenvironment: from molecular mechanisms to therapeutic strategies

News Publication Date:
24-Jul-2025

Web References:
https://www.cancerbiomed.org/content/early/2025/07/24/j.issn.2095-3941.2025.0115

References:
DOI: 10.20892/j.issn.2095-3941.2025.0115

Image Credits:
Cancer Biology & Medicine

Keywords:
Tumor microenvironments